Alterity Therapeutics Limited Stock Shares Owned By Insiders
| PRNAF Stock | USD 0 0.00 0.00% |
Fundamental analysis of Alterity Therapeutics allows traders to better anticipate movements in Alterity Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Alterity |
Alterity Therapeutics Limited Company Shares Owned By Insiders Analysis
Alterity Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Alterity Therapeutics Shares Owned By Insiders | 15.14 % |
Most of Alterity Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterity Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 15.14% of Alterity Therapeutics Limited are shares owned by insiders. This indicator is about the same for the Healthcare average (which is currently at 15.18) sector and 6.77% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 50.05% lower than that of the firm.
Alterity Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Alterity Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 3.12 X | |||
| Gross Profit | 4.76 M | |||
| EBITDA | (15.08 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 34.81 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 117.49 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 7.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (12.34 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.87 | |||
| Market Capitalization | 18.77 M | |||
| Total Asset | 41.36 M | |||
| Retained Earnings | (125 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 91.2 | |||
| Net Asset | 41.36 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.